These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 15004266)

  • 1. Hypertension and cardiovascular risk assessment in dialysis patients.
    Locatelli F; Covic A; Chazot C; Leunissen K; Luño J; Yaqoob M;
    Nephrol Dial Transplant; 2004 May; 19(5):1058-68. PubMed ID: 15004266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension in dialysis: pathophysiology and treatment.
    D'Amico M; Locatelli F
    J Nephrol; 2002; 15(4):438-45. PubMed ID: 12243377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
    Pede S; Lombardo M
    Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardioprotection: an essential component for predialysis chronic renal failure treatment].
    Jungers P; Qualim Z; Nguyen-Khoa T; Massy Z; London G
    Nephrologie; 2003; 24(2):79-88. PubMed ID: 12723513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.
    Filippi A; Paolini I; Innocenti F; Mazzaglia G; Battaggia A; Brignoli O
    J Hum Hypertens; 2009 Nov; 23(11):758-63. PubMed ID: 19242492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of guidelines for the management of hypertension in cardiovascular risk scoring of renal patients.
    Mazzaferro S; Barresi G; Baldinelli M; Malagnino E; Matera G; Otranto G; Pasquali M; Pugliese F
    Clin Ter; 2006; 157(4):327-32. PubMed ID: 17051969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac disease in chronic uremia: can it explain the reverse epidemiology of hypertension and survival in dialysis patients?
    Foley RN
    Semin Dial; 2004; 17(4):275-8. PubMed ID: 15250917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension goals in advanced-stage kidney disease.
    Hopkins K; Bakris GL
    Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S92-4. PubMed ID: 19996011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension and survival in hemodialysis patients.
    Lynn KL
    Semin Dial; 2004; 17(4):270-4. PubMed ID: 15250916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [French as 2005-recommendations on the management of arterial hypertension].
    Chamontin B; Halimi JM
    Arch Mal Coeur Vaiss; 2007 Jan; 100(1):42-6. PubMed ID: 17405553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of cardiovascular risk factors in end-stage renal disease.
    Covic A; Gusbeth-Tatomir P; Goldsmith DJ
    J Nephrol; 2003; 16(4):476-86. PubMed ID: 14696749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diminished glomerular filtration rate as a marker of chronic kidney disease in hypertensive patients].
    Grabysa R; Cholewa M
    Pol Merkur Lekarski; 2008 Jun; 24(144):487-91. PubMed ID: 18702327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal composition of the dialysate, with emphasis on its influence on blood pressure.
    Locatelli F; Covic A; Chazot C; Leunissen K; Luño J; Yaqoob M
    Nephrol Dial Transplant; 2004 Apr; 19(4):785-96. PubMed ID: 15031331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.